Market revenue in 2021 | USD 23.8 million |
Market revenue in 2030 | USD 164.0 million |
Growth rate | 23.9% (CAGR from 2021 to 2030) |
Largest segment | Serum biomarkers |
Fastest growing segment | Hepatic Fibrosis Biomarkers |
Historical data | 2018 - 2020 |
Base year | 2021 |
Forecast period | 2022 - 2030 |
Quantitative units | Revenue in USD million |
Market segmentation | Serum Biomarkers, Hepatic Fibrosis Biomarkers, Apoptosis Biomarkers, Oxidative Stress Biomarkers |
Key market players worldwide | Genfit SA, Siemens AG, Quest Diagnostics Inc, AstraZeneca PLC, Meridian Bioscience, Labcorp Holdings Inc, Pfizer Inc, Bristol-Myers Squibb Co |
No credit card required*
Name | Profile | # Employees | HQ | Website |
---|
The databook is designed to serve as a comprehensive guide to navigating this sector. The databook focuses on market statistics denoted in the form of revenue and y-o-y growth and CAGR across the globe and regions. A detailed competitive and opportunity analyses related to non-alcoholic steatohepatitis biomarkers market will help companies and investors design strategic landscapes.
Serum biomarkers was the largest segment with a revenue share of 32.77% in 2021. Horizon Databook has segmented the France non-alcoholic steatohepatitis biomarkers market based on serum biomarkers, hepatic fibrosis biomarkers, apoptosis biomarkers, oxidative stress biomarkers covering the revenue growth of each sub-segment from 2018 to 2030.
The active form of NAFLD, NASH, is characterized by hepatic necrotizing inflammation and accelerated fibrosis progression. The need for NAFLD and NASH biomarkers for prognostication, monitoring, and patient selection for treatment is urgent given the rising number of patients suffering from NASH-related end-stage liver disease and the potential for pharmacological therapies.
This need is especially important because the value of liver biopsies is constrained by their invasiveness, low patient acceptance, and sample variability. To develop novel NASH biomarkers, research institutes and key players are forming research collaborations.
For instance, in February 2021, Inventiva entered into a research collaboration with Faculty of Medicine of Angers University for developing NASH resolution and fibrosis improvement composite biomarker score to identify patients responding to lanifibranor.
Horizon Databook provides a detailed overview of country-level data and insights on the France non-alcoholic steatohepatitis biomarkers market , including forecasts for subscribers. This country databook contains high-level insights into France non-alcoholic steatohepatitis biomarkers market from 2018 to 2030, including revenue numbers, major trends, and company profiles.
Sign up and get instant basic access to databook, upgrade
when ready, or enjoy our
free plan indefinitely.
Included in Horizon account